Results 171 to 180 of about 17,592 (206)

Real-world outcomes of palbociclib plus endocrine therapy in elderly patients with HR+/HER2- advanced breast cancer in Japan: a subgroup analysis of the P-BRIDGE study by age group. [PDF]

Breast Cancer
Masuda H, Nagai SE, Hattori M, Yoshinami T, Okamura T, Watanabe K, Nakayama T, Tsuneizumi M, Takabatake D, Harao M, Yoshino H, Mori N, Yasojima H, Oshiro C, Iwase M, Yamaguchi M, Sangai T, Sasada S, Ishida T, Futamura M, Oda H, Muramatsu Y, Masuda N.   +22 more
europepmc   +1 more source

Corrigendum to "Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancer" [The Breast 86 (2026) 104744]. [PDF]

Breast
Brufsky A, Layman RM, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Cottu P, Curigliano G, Rugo HS.   +9 more
europepmc   +1 more source

CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction. [PDF]

Nat Commun
Luo L, Wang Y, Bui T, Jiang X, Chen MK, Rao X, Mohammadhosseinpour S, Li M, Kim S, Kim RY, Kamaliasl S, Ulizio CW, Tsavachidis S, Navarro-Yepes J, Kettner NM, Wingate H, Meric-Bernstam F, Hunt KK, Wang J, Faia K, Keyomarsi K.   +20 more
europepmc   +1 more source

Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care. [PDF]

Breast Cancer Res Treat
Brufsky AM, Finn RS, Metzger O, Goncalves R, Huang-Bartlett C, Sreenivasan S, Nur U, Davies J, Grigorenko A, Long GH.   +9 more
europepmc   +1 more source

The kinase inhibitor palbociclib binds to HIV TAR RNA with very low nanomolar affinity and exquisite specificity. [PDF]

Nucleic Acids Res
Reddy Ramireddy R, Shortridge MD, Vidalala V, Chaubey B, Tang C, Olsen GL, Varani G.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Palbociclib

Reactions Weekly, 2019
  +16 more sources

Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells

Cancer Letters, 2018
Palbociclib is a specific inhibitor of CDK4/6 and has been shown to provide a survival benefit in hormone receptor-positive advanced breast cancer. TCGA database reported that about half of gastric cancers exhibit abnormalities in cell-cycle-related ...
Seongyeong Kim, Kyung-Hun Lee, Do-Youn Oh   +2 more
exaly   +2 more sources